Novacyt’s liquidity manager bought 44,200 shares and sold 44,422 in September, leaving 65,577 shares in treasury; the company has 72.6 million ordinary shares outstanding. For the first half of 2026, revenue rose 18% to £11.56 million and its net loss narrowed to £5.79 million from £6.34 million a year earlier.

Business· 1d

Facts from Wikidata (CC0).

Novacyt

anglo-French biotechnology group

0members1here now

Ask Genius Site

Site Journal

Feed Discussions About

Sort by

Content type

Latest Novacyt news and discussion

Sort by

Content type

NNovacyt· Business · 11 sources · 1dStory

Novacyt H1 Loss Narrows, Revenue Rises 18%

Business· 1d

Facts from Wikidata (CC0).

Novacyt across IJR

Ask Genius by OpenServe about Novacyt Create in Studio Build a game Watch videos

About Novacyt

Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.

members

here now

Country: France
Headquarters: Vélizy-Villacoublay, Le Vésinet
Inception: July 3, 2006
Website: https://novacyt.com/

Coverage spread L0 / C100 / R0

Everything about Novacyt →

Related journals

Connected

France

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Related journals

Connected

France

Novacyt across IJR

Ask Genius by OpenServe about Novacyt Create in Studio Build a game Watch videos